User:Mr. Ibrahem/Adagrasib

Adagrasib, sold under the brand name Krazati, is a medication used to treat non-small cell lung cancer (NSCLC). Specifically it is used for KRAS G12C-mutated advanced cancer that has failed at list one other treatment. It is taken by mouth.

Common side effects include diarrhea, nausea, musculoskeletal pain, liver problems, kidney problems, shortness of breath, low potassium, low sodium, low white blood cells, and swelling. Other side effects may include QT prolongation and pneumonitis. It is an inhibitor of the RAS GTPase family.

Adagrasib was approved for medical use in the United States in 2022. In the United States it costs about 237,000 USD per year as of 2022.